Company HCW Biologics Inc.

Equities

HCWB

US40423R1059

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:30:00 15/05/2024 BST			5-day change	1st Jan Change
1.16 ^USD	+0.87%		0.00%	-5.31%

04-01	HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-01	HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-Î² and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Number of employees: 45

USD in Million	2022	Weight	2023	Weight	Delta
Novel Immunotherapies 100.0 %	7	100.0 %	3	100.0 %	-57.72%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	7	100.0 %	3	100.0 %	-57.72%

Managers	Title	Age	Since
Hing Wong FOU	Founder	70	01/04/18
Rebecca Byam DFI	Director of Finance/CFO	68	30/09/19
Peter Rhode CTO	Chief Tech/Sci/R&D Officer	66	30/04/19
Raquel Diaz HRO	Human Resources Officer	-	31/03/18
Nicole Valdivieso LAW	General Counsel	-	31/07/19
Jin-an Jiao PRN	Corporate Officer/Principal	65	30/04/19
Lee Flowers PRN	Corporate Officer/Principal	78	31/08/19

Members of the board	Title	Age	Since
Scott Garrett CHM	Chairman	73	30/04/21
Hing Wong FOU	Founder	70	01/04/18
Rick Greene BRD	Director/Board Member	59	30/04/21
Lisa Giles BRD	Director/Board Member	65	24/10/21
Gary Winer BRD	Director/Board Member	64	24/10/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,823,394	18,040,269 ( 47.70 %)	0	47.70 %

Name	Equities	%	Valuation
Hing Wong 42.45 %	16,054,156	42.45 %	23 M $
Axone Capital 5.036 %	1,904,762	5.036 %	3 M $
Rebecca Byam 3.654 %	1,381,909	3.654 %	2 M $
Scott Garrett 0.7082 %	267,858	0.7082 %	391 073 $
Lee Flowers 0.5030 %	190,238	0.5030 %	277 747 $
HighTower Advisors LLC 0.4754 %	179,810	0.4754 %	262 523 $
Avantax Planning Partners, Inc. 0.4753 %	179,777	0.4753 %	262 474 $
Geode Capital Management LLC 0.4608 %	174,284	0.4608 %	254 455 $
Cresset Asset Management LLC 0.3490 %	131,990	0.3490 %	192 705 $
Pullen Investment Management LLC 0.2250 %	85,116	0.2250 %	124 269 $

HCW Biologics Inc.

2929 North Commerce Parkway

33025, Miramar

http://www.hcwbiologics.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.16 USD

Average target price

4 USD

Spread / Average Target

+244.83%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HCW BIOLOGICS INC.	-5.31%	43.5M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	111B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.58%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.54B
LEGEND BIOTECH CORPORATION	-23.95%	8.09B

Bio Therapeutic Drugs